GREENWICH LIFESCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
GREENWICH LIFESCIENCES, INC. (GLSI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 893.18 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 893.18K shares, a 0.00% change year-over-year.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 893.18K shares, a 0.00% change from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 893.18K shares, a 0.00% change from fiscal 2023.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 893.18K shares, a 0.00% change from fiscal 2022.
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 893.18K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 893.18K shares 10-Q · filed 2026-08-11 | 893.18K shares derived: sum of 3 quarters · filed 2026-08-11 | 893.18K shares derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | 893.18K shares 10-Q · filed 2026-06-04 | 893.18K shares derived: sum of 2 quarters · filed 2026-06-04 | 893.18K shares derived: sum of 3 quarters · filed 2026-06-04 | 893.18K shares derived: sum of 4 quarters · filed 2026-06-04 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | 0.00 shares derived: sum of 2 quarters · filed 2026-06-01 | 0.00 shares derived: sum of 3 quarters · filed 2026-06-01 | 893.18K shares 10-K · filed 2026-06-01 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-14 | 893.18K shares 10-Q · filed 2025-11-14 | 893.18K shares derived: sum of 4 quarters · filed 2026-06-01 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 893.18K shares 10-Q · filed 2025-08-14 | 893.18K shares derived: sum of 3 quarters · filed 2026-06-01 | 893.18K shares derived: sum of 4 quarters · filed 2026-06-01 | |
| 2025-03-31 | 893.18K shares 10-Q · filed 2025-05-20 | 893.18K shares derived: sum of 2 quarters · filed 2026-06-01 | 893.18K shares derived: sum of 3 quarters · filed 2026-06-01 | 893.18K shares derived: sum of 4 quarters · filed 2026-06-01 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | 0.00 shares derived: sum of 2 quarters · filed 2026-06-01 | 0.00 shares derived: sum of 3 quarters · filed 2026-06-01 | 893.18K shares 10-K · filed 2026-06-01 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-14 | 893.18K shares 10-Q · filed 2024-11-14 | 878.00K shares derived: sum of 4 quarters · filed 2025-04-15 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 893.18K shares 10-Q · filed 2024-08-14 | 878.00K shares derived: sum of 3 quarters · filed 2025-04-15 | 878.00K shares derived: sum of 4 quarters · filed 2025-04-15 | |
| 2024-03-31 | 893.18K shares 10-Q · filed 2024-05-20 | 878.00K shares derived: sum of 2 quarters · filed 2025-04-15 | 878.00K shares derived: sum of 3 quarters · filed 2025-04-15 | 878.00K shares derived: sum of 4 quarters · filed 2025-04-15 | |
| 2023-12-31 | -15.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -15.18K shares derived: sum of 2 quarters · filed 2025-04-15 | -15.18K shares derived: sum of 3 quarters · filed 2025-04-15 | 893.18K shares 10-K · filed 2025-04-15 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-19 | 0.00 shares derived: sum of 2 quarters · filed 2023-10-19 | 908.36K shares 10-Q · filed 2023-10-19 | ||
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | 908.36K shares 10-Q · filed 2023-08-21 | |||
| 2023-03-31 | 908.36K shares 10-Q · filed 2023-05-22 | ||||
| 2022-12-31 | 893.18K shares 10-K · filed 2024-04-15 | ||||
| 2022-06-22 | 1.50M shares 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |